Gefjon Pharma

Gefjon Pharma is a biotechnology company focused on developing innovative platform technology for the cost-effective production of bio-industrials and therapeutics. Their core innovation lies in a unique hyper-vesiculating outer membrane vesicle (OMV) technology combined with an optimized extraction method. The company's initial product is a revolutionary broad-protective bacterial E. coli vaccine specifically targeting poultry production. This vaccine aims to significantly reduce the global consumption of antimicrobials, thereby minimizing the development of antimicrobial resistance (AMR), improving animal welfare, and reducing CO2 emissions and food waste, while simultaneously increasing customer profits.

Founded in 2023, Gefjon Pharma was established by a team of co-founders: Anders Miki Bojesen (Chief Scientific Officer), Fabio Antenucci (Chief Technology Officer), Thomas Buthler (Chief Operations & Quality Officer), and Torben Hald (Chief Executive Officer). The company's mission is to disrupt the poultry E. coli vaccine industry and become a market leader within the next 5-10 years, driven by the vision of making cost-effective therapeutics available for everyone, everywhere.

As a biotech company, Gefjon Pharma is a recipient of investments and grants rather than an investment firm. The company has garnered significant recognition and support, including being selected for BioInnovation Institute’s Venture House program and awarded DKK 10.5 million in follow-on financing in March 2026. They have also been granted Small and Medium-Sized Enterprise (SME) status from the European Medicines Agency (EMA) in October 2025. Further support includes an InnoBooster Grant and a GUDP (Grønt Udviklings & Demonstrationsprogram) grant for their "ColiControl" project, both awarded in 2024. Gefjon Pharma also secured exclusive rights to commercialize its patentable OMV E. coli vaccine in December 2024.

The leadership team at Gefjon Pharma brings a wealth of experience, with over 75 years of combined expertise in research, development, pharmaceutical production, business, and business development. This diverse background provides a strong foundation for building a successful company in the biotechnology sector. The company also benefits from an experienced advisory board, including experts from DelsiTech, ABICS GmbH, CentralVetPharma, Ellab A/S, Vetgruppen, UCPH Lighthouse, and Lyhne Life Partners.